[ { "@graph" : [ { "@id" : "http://purl.org/np/RAA6yBWbyBjegdp0jAohUmaheBFZ9JzzrOt_GqjO_Bbj8", "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ], "http://www.nanopub.org/nschema#hasAssertion" : [ { "@id" : "http://purl.org/np/RAA6yBWbyBjegdp0jAohUmaheBFZ9JzzrOt_GqjO_Bbj8#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance" : [ { "@id" : "http://purl.org/np/RAA6yBWbyBjegdp0jAohUmaheBFZ9JzzrOt_GqjO_Bbj8#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo" : [ { "@id" : "http://purl.org/np/RAA6yBWbyBjegdp0jAohUmaheBFZ9JzzrOt_GqjO_Bbj8#pubinfo" } ] } ], "@id" : "http://purl.org/np/RAA6yBWbyBjegdp0jAohUmaheBFZ9JzzrOt_GqjO_Bbj8#Head" }, { "@graph" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_9008", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id" : "http://purl.org/np/RAA6yBWbyBjegdp0jAohUmaheBFZ9JzzrOt_GqjO_Bbj8#association", "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_9008" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ { "@id" : "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ { "@id" : "https://identifiers.org/drugbank:DB00005" } ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "enbrel is a tumor necrosis factor tnf blocker indicated for the treatment of rheumatoid arthritis ra 1 1 polyarticular juvenile idiopathic arthritis jia in patients aged 2 years or older 1 2 psoriatic arthritis psa 1 3 ankylosing spondylitis as 1 4 plaque psoriasis pso in patients 4 years or older 1 5 enbrel is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis ra enbrel can be initiated in combination with methotrexate mtx or used alone enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis jia in patients ages 2 and older enbrel is indicated for reducing signs and symptoms inhibiting the progression of structural damage of active arthritis and improving physical function in patients with psoriatic arthritis psa enbrel can be used with or without methotrexate enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis as enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis pso who are candidates for systemic therapy or phototherapy" } ], "https://w3id.org/biolink/vocab/association_type" : [ { "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation" } ], "https://w3id.org/biolink/vocab/provided_by" : [ { "@id" : "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/relation" : [ { "@id" : "https://w3id.org/um/neurodkg/SymptomaticReliefIndication" } ] }, { "@id" : "https://identifiers.org/drugbank:DB00005", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Drug" } ] } ], "@id" : "http://purl.org/np/RAA6yBWbyBjegdp0jAohUmaheBFZ9JzzrOt_GqjO_Bbj8#assertion" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAA6yBWbyBjegdp0jAohUmaheBFZ9JzzrOt_GqjO_Bbj8#assertion", "http://www.w3.org/ns/prov#wasAttributedTo" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ] } ], "@id" : "http://purl.org/np/RAA6yBWbyBjegdp0jAohUmaheBFZ9JzzrOt_GqjO_Bbj8#provenance" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAA6yBWbyBjegdp0jAohUmaheBFZ9JzzrOt_GqjO_Bbj8", "http://purl.org/dc/terms/created" : [ { "@type" : "http://www.w3.org/2001/XMLSchema#dateTime", "@value" : "2021-06-12T13:20:48.407+02:00" } ], "http://purl.org/dc/terms/creator" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ { "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ { "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ { "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs" } ] }, { "@id" : "http://purl.org/np/RAA6yBWbyBjegdp0jAohUmaheBFZ9JzzrOt_GqjO_Bbj8#sig", "http://purl.org/nanopub/x/hasAlgorithm" : [ { "@value" : "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey" : [ { "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature" : [ { "@value" : "Y1alPKiqaY5r5Ka/vbfc8WisGbR3ltt2uCUCmGYcq8RROll6uTiHxu9bwlSweQnGORHo3UZWSi4n78NeOghLql93C3ibhIueX9fDwCIGauSLcHgzc3d8fMY7ow9s15McbqD1Hm/HaPyXNh8oO/LSfVXSUBJsIIisH6S547NmFW0=" } ], "http://purl.org/nanopub/x/hasSignatureTarget" : [ { "@id" : "http://purl.org/np/RAA6yBWbyBjegdp0jAohUmaheBFZ9JzzrOt_GqjO_Bbj8" } ] } ], "@id" : "http://purl.org/np/RAA6yBWbyBjegdp0jAohUmaheBFZ9JzzrOt_GqjO_Bbj8#pubinfo" } ]